Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Announces $13 Million Equity Financing
6/13/2011 7:12:36 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study
5/6/2011 9:15:47 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting
5/5/2011 10:22:01 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Submits Two Supplemental NDAs to FDA for VELCADE
4/26/2011 8:52:43 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) and Sunesis Pharmaceuticals, Inc. (SNSS) Announce Collaboration for Kinase Inhibitors in Oncology; Sunesis Receives a $4 Million Payment
4/5/2011 7:08:06 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Becomes First Licensed Customer for BioClinica, Inc.’s New Enterprise Demand Aggregator
3/30/2011 10:16:55 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Selects OrgPlus to Deliver Accurate Workforce Insight
7/13/2010 3:33:31 PM
More...
|
Seattle Genetics, Inc. (SGEN) and Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
2/3/2010 10:14:32 AM
More...
|
Seattle Genetics, Inc. (SGEN) Announces Antibody-Drug Conjugate Collaboration With Millennium: The Takeda Oncology Company
4/6/2009 7:23:44 AM
More...
|
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) New Data Will Be Presented at ASH on VELCADE(R) (Bortezomib) for Injection-Based Therapies in Multiple Myeloma and Non-Hodgkin's Lymphoma
11/18/2008 10:42:36 AM
More...
|
|